ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms

Fave, Gianfranco Delle; O’Toole, Dermot; Sundín, Anders; Taal, Babs G.; Ferollà, Piero; Ramage, John; Ferone, Diego; Ito, Tetsuhide; Weber, Wolfgang; Zeng, Zheng-pei; Herder, Wouter W. de; Pascher, Andreas; Ruszniewski, Philippe

doi:10.1159/000443168

Cited by 423 publications

(531 citation statements)

References 35 publications

Supporting

Mentioning

476

Contrasting

Unclassified

Order By: Relevance

“…sociated with the disease is less than 10% [6]. Blood serum gastrin is significantly elevated, whereas gastric pH is very low.…”

Section: Szkolenie Podyplomowementioning

confidence: 97%

“…The prevalence is estimated at 1-2 cases per 1,000,000 people per year, (1.2/1,000,000 males, 1.8/1,000,000 females). In the years 1981-2000, an 8-9-fold increase in the diagnosis of g-NENs was observed, due to the continuously extending indications for endoscopic examinations [5,6].…”

Section: Neuroendocrine Neoplasms Of the Stomachmentioning

confidence: 99%

“…They are rarely invasive. 2-5% of cases are metastatic, and the ability to produce metastases increases along with the tumour size [6]. They are almost always slowly growing tumours with good prognosis -mortality rates have not been described, despite the disease advancement (up to 100% of patients with 10-year survival rate).…”

Section: Typementioning

confidence: 99%

“…50-100% of the lesions are associated with metastases to the lymph nodes and liver. Deaths due to g-NEC occur in 25-30% of cases, depending on the level of differentiation and the presence of metastases [6]. Blood serum gastrin concentrations and gastric pH are normal.…”

Section: Typementioning

confidence: 99%

“…Moreover, gastric neoplasms with mixed endocrine and exocrine characteristics have also been described [11]. Presently, the literature presents 68 such cases, but there are no data available on survival [6].…”

Section: Typementioning

confidence: 99%

See 4 more Smart Citations

Nowotwory neuroendokrynne żołądka i dwunastnicy z uwzględnieniem gastrinoma (zasady postępowania rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)

Lipiński¹,

Rydzewska²,

Fołtyn³

et al. 2017

Endokrynologia Polska

View full text Add to dashboard Cite

“…sociated with the disease is less than 10% [6]. Blood serum gastrin is significantly elevated, whereas gastric pH is very low.…”

Section: Szkolenie Podyplomowementioning

confidence: 97%

Section: Neuroendocrine Neoplasms Of the Stomachmentioning

confidence: 99%

Section: Typementioning

confidence: 99%

Section: Typementioning

confidence: 99%

Section: Typementioning

confidence: 99%

See 3 more Smart Citations

Nowotwory neuroendokrynne żołądka i dwunastnicy z uwzględnieniem gastrinoma (zasady postępowania rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)

Lipiński¹,

Rydzewska²,

Fołtyn³

et al. 2017

Endokrynologia Polska

View full text Add to dashboard Cite

Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors

et al. 2018

View full text Add to dashboard Cite

There is no consensus on optimal follow-up for completely resected gastroenteropancreatic neuroendocrine tumors. Published guidelines for follow-up are complex and emphasize closer surveillance in the first 3 years after resection. Neuroendocrine tumors have a different pattern and timescale of recurrence, and thus require more practical and tailored follow-up. The Commonwealth Neuroendocrine Tumour Collaboration convened an international multidisciplinary expert panel, in collaboration with the North American Neuroendocrine Tumor Society, to create patient-centered follow-up recommendations for completely resected gastroenteropancreatic neuroendocrine tumors. This panel used the RAND/UCLA (University of California, Los Angeles) Appropriateness Method to generate recommendations. A large international survey was conducted outlining current the surveillance practice of neuroendocrine tumor practitioners and shortcomings of the current guidelines. A systematic review of available data to date was supplemented by recurrence data from 2 large patient series. The resultant guidelines suggest follow-up for at least 10 years for fully resected small-bowel and pancreatic neuroendocrine tumors and also identify clinical situations in which no follow-up is required. These recommendations stratify follow-up strategies based on evidence-based prognostic factors that allow for a more individualized patient-centered approach to this complex and heterogeneous malignant neoplasm.

show abstract